Company Filing History:
Years Active: 2002
Title: John J M Bergeron: Innovator in Protein Folding and UGGT Activity
Introduction
John J M Bergeron is a notable inventor based in Pointe Claire, Canada. He has made significant contributions to the field of protein folding and the understanding of glycoprotein glucosyltransferase (UGGT) activity. With a total of 2 patents, his work has implications for treating and diagnosing protein trafficking disorders.
Latest Patents
One of his latest patents is titled "Method for folding unfolded proteins." This invention relates to methods of treating and diagnosing protein trafficking disorders and controlling secretory protein production. The methods involve exposing an unfolded protein to a biological preparation comprising ERp57 in combination with calnexin or calreticulin under conditions that permit the folding of the unfolded protein.
Another significant patent is "Methods for screening UDP-glucose:glycoprotein glucosyltransferase (UGGT) activity and nucleic acid encoding for UGGT." This invention outlines a method for determining the effect of a test sample on UGGT activity. The method includes exposing an acceptor substrate of UGGT to a labeled donor in the presence of the test sample and UGGT, followed by detecting the amount of donor transferred to the acceptor substrate. A decrease in donor intake compared to a control indicates that the test sample is a UGGT stimulator or inhibitor.
Career Highlights
John J M Bergeron is affiliated with the National Research Council of Canada, where he has been involved in groundbreaking research. His work has contributed to advancements in the understanding of protein dynamics and their applications in biotechnology.
Collaborations
He has collaborated with notable colleagues such as Daniel C Tessier and David Y Thomas, further enhancing the impact of his research through teamwork and shared expertise.
Conclusion
John J M Bergeron is a distinguished inventor whose work in protein folding and UGGT activity has the potential to influence medical and biotechnological fields. His contributions continue to pave the way for innovative solutions in protein-related disorders.